A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors
Cogent Biosciences, Inc.
Cogent Biosciences, Inc.
Eli Lilly and Company
Merck Sharp & Dohme LLC
Tango Therapeutics, Inc.
Astellas Pharma Inc
InnoPharmax Inc.
Novartis
Travera Inc
Virogin Biotech Ltd.
J-Pharma Co., Ltd.
Tango Therapeutics, Inc.
Taiho Oncology, Inc.
Hutchmed
Merck Sharp & Dohme LLC
Jazz Pharmaceuticals
Rigel Pharmaceuticals
Arbele Limited
Alentis Therapeutics AG
Eli Lilly and Company
Taiho Oncology, Inc.
Hoffmann-La Roche
Imugene Limited
AstraZeneca
Eisai Inc.
Elevar Therapeutics
Seagen Inc.
Servier
Arvinas Inc.
Myeloid Therapeutics
Servier
New Phase Ltd.
Amgen
xCures
DualityBio Inc.
Bold Therapeutics, Inc.
SOFIE
Genfit